In recent years, the pharmaceutical industry has witnessed significant advancements in the treatment of chronic obstructive pulmonary disease (COPD). One such breakthrough is the development of Aclidinium Bromide Drug, a long-acting inhaled anticholinergic drug that…
In a major breakthrough for precision oncology, Fulzerasib tablets have emerged as a promising treatment for patients with solid tumors harboring the KRAS G12C mutation. Developed by Innovent Biologics and GenFleet Therapeutics, Fulzerasib is an…
In a significant advancement in the fight against leukemia, Iclusig (ponatinib) continues to demonstrate its effectiveness as a potent tyrosine kinase inhibitor (TKI) for patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic…
April 2023 – The U.S. Food and Drug Administration (FDA) today approved Qalsody (tofersen) for the treatment of amyotrophic lateral sclerosis (ALS) caused by mutations in the superoxide dismutase 1 (SOD1) gene. This approval brings…
China’s National Drug Administration (NMPA) has officially approved the marketing application for the novel anti-hepatitis B virus drug Pradefovir Mesylate. This breakthrough provides a new treatment option for patients with chronic hepatitis B (HBV), marking…
Recently, the U.S. Food and Drug Administration (FDA) announced the accelerated approval of Jaypirca (generic name: pirtobrutinib) for the treatment of patients with relapsed or refractory mantle cell lymphoma (MCL) who have previously received BTK…
In October 2018, the U.S. Food and Drug Administration (FDA) approved talazoparib, a novel PARP inhibitor, for the treatment of patients with HER2-negative locally advanced or metastatic breast cancer harboring mutations in the BRCA gene.…
In October 2021, the U.S. Food and Drug Administration (FDA) approved a novel drug, Tavneos (avacopan), for the treatment of ANCA-associated vasculitis (AAV), news that brings new treatment options to patients suffering from this rare…
Garsorasib Company Today announced a significant milestone in the development of its flagship drug, Garsorasib, a novel KRAS G12C inhibitor designed to treat non-small cell lung cancer (NSCLC) and other solid tumors. This groundbreaking therapy has…
Zevorcabtagene Autoleucel is a CAR-T cell therapy targeting B-cell maturation antigen (BCMA) by genetically engineering a patient’s own T cells to precisely recognize and kill multiple myeloma cells that express BCMA, a marker highly expressed…
Taletrectinib Adipate Capsules have been approved by the China National Drug Administration (NMPA) for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who have received prior ROS1…
In the ever-evolving field of oncology, the development of targeted therapies has revolutionized the way we approach cancer treatment. One such advancement is the emergence of Welireg (belzutifan), a novel therapeutic agent that has shown promise…
